Thinking of joining a study?

Register your interest

Become a volunteer?

Clinical trials for Cancer in United States

7255 results

Sort By:

An Informational and Supportive Care Intervention for Patients With Locally Advanced Rectal Cancer

Study ID: NCT05914766
Start Date: 2023-09-21
End Date: 2028-12
Study Type

Interventional

Study Phase

Not Applicable

No. of Participants

80

Intervention / Treatment

PATHWAYS

Enhanced usual care

Sponsor

Massachusetts General Hospital

Source: clinicaltrials.gov

Share:
Add to list

Myriad™ Augmented Soft Tissue Reconstruction Registry

Study ID: NCT05243966
Start Date: 2022-01-10
End Date: 2029-01
Study Type

Observational

Study Phase

Not Applicable

No. of Participants

800

Intervention / Treatment

Myriad Matrix™ and Myriad Morcells™

Sponsor

Aroa Biosurgery Limited

Source: clinicaltrials.gov

Share:
Add to list

Gene Signatures to Guide HR+MBC Therapy in a Diverse Cohort

Study ID: NCT05693766
Start Date: 2023-09-11
End Date: 2037-08-31
Study Type

Interventional

Study Phase

Phase2

No. of Participants

64

Intervention / Treatment

Capecitabine

Endocrine-therapy

MammoPrint ® and BluePrint assays

Sponsor

Sonya Reid

Source: clinicaltrials.gov

Share:
Add to list

Gastrointestinal Biomarkers in Tissue and Biological Fluid Samples from Colorectal Cancer Patients

Study ID: NCT00899626
Start Date: 2002-06
End Date: 2045-10
Study Type

Observational

Study Phase

Not Applicable

No. of Participants

5000

Intervention / Treatment
Sponsor

Vanderbilt University Medical Center

Source: clinicaltrials.gov

Share:
Add to list

A Trial to Find Out How Safe REGN5668 is and How Well it Works When Given With Either Cemiplimab or REGN4018

Study ID: NCT04590326
Start Date: 2020-12-09
End Date: 2027-04-27
Study Type

Interventional

Study Phase

Phase2

No. of Participants

612

Intervention / Treatment

REGN5668

Cemiplimab

Regn4018

Sarilumab

Sponsor

Regeneron Pharmaceuticals

Source: clinicaltrials.gov

Share:
Add to list

BP1001-A in Patients With Advanced or Recurrent Solid Tumors

Study ID: NCT04196257
Start Date: 2022-08-19
End Date: 2027-10
Study Type

Interventional

Study Phase

Phase1

No. of Participants

50

Intervention / Treatment

BP1001-A (Liposomal Grb2 Antisense Oligonucleotide)

BP1001-A (Liposomal Grb2 Antisense Oligonucleotide) with paclitaxel

Sponsor

Bio-Path Holdings, Inc.

Source: clinicaltrials.gov

Share:
Add to list

Comprehensive Molecular and Clinical Evaluation of Pediatric and Adult MDS

Study ID: NCT05350748
Start Date: 2022-08-18
End Date: 2042-05-01
Study Type

Observational

Study Phase

Not Applicable

No. of Participants

1100

Intervention / Treatment
Sponsor

National Cancer Institute (NCI)

Source: clinicaltrials.gov

Share:
Add to list

Phase 1/2a Study of Belantamab Mafodotin in Relapsed or Refractory AL Amyloidosis

Study ID: NCT05145816
Start Date: 2024-02-15
End Date: 2026-09-01
Study Type

Interventional

Study Phase

Phase2

No. of Participants

37

Intervention / Treatment

Belantamab Mafodotin 2.5 mg/kg (8 weeks)

Mafodotin Belantamab 1.9 mg/kg (8 weeks)

Mafodotin Belantamab 1.4 mg/kg (12 weeks)

Mafodotin Beliantamab 1.9 mg/kg (12 weeks)

Belantamab mafodotin every 4 weeks, 6 weeks,8 weeks, or 12 weeks as determined by Part 1 recommended dosages

Mafodotin Belientamab 1.0 mg/kg (12 weeks)

Sponsor

University of Texas Southwestern Medical Center

Source: clinicaltrials.gov

Share:
Add to list

Paxalisib (GDC-0084) In Recurrent Or Refractory PCNSL

Study ID: NCT04906096
Start Date: 2021-06-01
End Date: 2027-12-01
Study Type

Interventional

Study Phase

Phase2

No. of Participants

25

Intervention / Treatment

Pawalib

Sponsor

Lakshmi Nayak, item

Source: clinicaltrials.gov

Share:
Add to list

AU409 for the Treatment of Advanced Primary Liver Cancers or Solid Tumor With Liver Metastatic Disease

Study ID: NCT05791448
Start Date: 2023-03-29
End Date: 2027-03-29
Study Type

Interventional

Study Phase

Phase1

No. of Participants

36

Intervention / Treatment

Biospecimen Collection

Computed Tomography

Magnetic Resonance Imaging

RNA Transcription Modulator AU-409

Sponsor

University of Southern California

Source: clinicaltrials.gov

Share:
Add to list